Dunhill Financial’s Revolution Medicines RVMD Stock Holding History

Dunhill Financial’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$405	Hold	2	–	–	﹤0.01%	1167
2026 Q1	$210	Hold	2	–	–	﹤0.01%	1244
2025 Q4	$172	Buy	+2	New	+$131	﹤0.01%	1163

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Dunhill Financial's RVMD Position: Q2 2026 in Review

Dunhill Financial held its Revolution Medicines (RVMD) position steady in Q2 2026 at 2 shares worth $405. The position accounts for ﹤0.01% of the portfolio, ranked #1167.

Dunhill Financial first reported a position in RVMD in Q4 2025 and has held it in 3 quarters since. 693 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Dunhill Financial held 2 shares of Revolution Medicines worth $405 as of Q2 2026.
Dunhill Financial left its Revolution Medicines share count unchanged in Q2 2026.
Revolution Medicines made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1167 holding.
Dunhill Financial first reported a position in Revolution Medicines in Q4 2025 and has held it in 3 quarters since.
693 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.